Torosyan, Hayarpi http://orcid.org/0000-0003-1576-0195
Paul, Michael D. http://orcid.org/0000-0001-8479-110X
Forget, Antoine
Lo, Megan
Diwanji, Devan
Pawłowski, Krzysztof
Krogan, Nevan J. http://orcid.org/0000-0003-4902-337X
Jura, Natalia http://orcid.org/0000-0001-5129-641X
Verba, Kliment A. http://orcid.org/0000-0002-2238-8590
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U54 CA209891, R35-GM139636, U54 CA209891, R35-GM139636)
U.S. Department of Health & Human Services | National Institutes of Health
UCSF Program for Breakthrough Biomedical Research
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 24 August 2022
Accepted: 16 May 2023
First Online: 19 June 2023
Competing interests
: N.J. is a founder of Rezo Therapeutics and a shareholder of Rezo Therapeutics, Sudo Therapeutics, and Type6 Therapeutics. N.J. is a SAB member of Sudo Therapeutics, Type6 Therapeutic and NIBR Oncology. The Jura laboratory has received sponsored research support from Genentech, Rezo Therapeutics and Type6 Therapeutics. The Krogan Laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche, and Rezo Therapeutics. Nevan Krogan has previously held financially compensated consulting agreements with the Icahn School of Medicine at Mount Sinai, New York and Twist Bioscience Corp. He currently has financially compensated consulting agreements with Maze Therapeutics, Interline Therapeutics, Rezo Therapeutics, and GEn1E Lifesciences, Inc. He is on the Board of Directors of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, and Interline Therapeutics. The other authors declare no competing interests.